Status:

TERMINATED

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Kidney Transplantation

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This study will assess the safety, efficacy and effect on quality of life of switching kidney transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a higher than t...

Eligibility Criteria

Inclusion

  • adult patients, \>=18 years of age;
  • first or second kidney transplant;
  • EC-MPS therapy for \>=6 months, with a stable dose for \>=2 months;
  • lower than recommended dose of EC-MPS (\<1440g/day) due to gastrointestinal complaints.

Exclusion

  • patients who have participated in this study before;
  • patients currently participating in another clinical trial, or who participated in one during the last 30 days.

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00420472

Start Date

March 1 2007

Last Update

November 20 2007

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Berlin, Germany, 10117

2

Berlin, Germany, 13353

3

Cologne, Germany, 51109

4

Dresden, Germany, 01307

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS. | DecenTrialz